Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

10.35 +0.14 (+1.37%)
Official Closing Price Updated: 7:00 PM EDT, Sep 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,611,538
Open 10.24
Bid (Size) 10.17 (10)
Ask (Size) 10.39 (10)
Prev. Close 10.21
Today's Range 10.07 - 10.38
52wk Range 8.010 - 19.35
Shares Outstanding 253,545,051
Dividend Yield 0.77%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
1 Surging Stock Worth Your Attention and 2 We Avoid
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage... 
Via StockStory
Topics Initial Public Offering
Johnson & Johnson's Hypothetical Rally: A Look at Potential 2025 Valuation Drivers
In a hypothetical scenario playing out just last week, leading up to September 27, 2025, Johnson & Johnson (NYSE: JNJ) experienced a significant stock rally, capturing the attention of investors and... 
Via MarketMinute
Topics Economy Intellectual Property

Performance

YTD
-30.8%
-30.8%
1 Month
+9.9%
+9.9%
3 Month
+6.9%
+6.9%
6 Month
-30.5%
-30.5%
1 Year
-45.9%
-45.9%

More News

Read More
Why Organon (OGN) Stock Is Trading Up Today
Via StockStory
Topics Artificial Intelligence Economy Initial Public Offering
Earnings Scheduled For August 5, 2025
Via Benzinga
A Look Ahead: Organon's Earnings Forecast
Via Benzinga
3 Stocks Under $50 We Find Risky
Via StockStory
US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
From Organon & Co.
Via Business Wire
3 Cash-Producing Stocks with Warning Signs
Via StockStory
1 Healthcare Stock Worth Investigating and 2 Facing Challenges
Via StockStory
Topics Stocks
Brookdale, Evolent Health, Fortrea, 10x Genomics, and Organon Stocks Trade Up, What You Need To Know
Via StockStory
Topics Artificial Intelligence Economy
OGN Q2 Deep Dive: Flat Sales, Margin Pressure, and Strategic Shifts Highlight Quarter
Via StockStory
3 of Wall Street’s Favorite Stocks We Find Risky
Via StockStory
Organon (OGN) Fiscal Q2 Revenue Beats 1%
Via The Motley Fool
Organon (NYSE:OGN) Surprises With Q2 Sales, Stock Soars
Via StockStory
Organon Reports Results for the Second Quarter Ended June 30, 2025
From Organon & Co.
Via Business Wire
Organon Earnings: What To Look For From OGN
Via StockStory
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
From Faruqi & Faruqi, LLP
Via Business Wire
Organon & Co. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2025 to Discuss Your Rights - OGN
Via NewMediaWire
Topics Fraud Lawsuit
Organon & Co. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2025 to Discuss Your Rights - OGN
Via TheNewswire.com
Topics Fraud Lawsuit
ORGANON FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Organon & Co. (OGN) Investors of the July 22nd Deadline and Urges Them to Inquire About Their Rights in Class Action Lawsuit
From Bragar Eagel & Squire
Via GlobeNewswire
Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025
From Organon & Co.
Via Business Wire
Deadline Soon: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
DEADLINE TOMORROW: Berger Montague Advises Organon & Co. (NYSE: OGN) Investors to Inquire About a Securities Fraud Class Action by July 22, 2025
From Berger Montague
Via GlobeNewswire
Organon & Co. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - OGN
Via NewMediaWire
Topics Fraud Lawsuit
Organon & Co. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - OGN
Via TheNewswire.com
Topics Fraud Lawsuit

Frequently Asked Questions

Is Organon & Co. Common Stock publicly traded?
Yes, Organon & Co. Common Stock is publicly traded.
What exchange does Organon & Co. Common Stock trade on?
Organon & Co. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Organon & Co. Common Stock?
The ticker symbol for Organon & Co. Common Stock is OGN on the New York Stock Exchange
What is the current price of Organon & Co. Common Stock?
The current price of Organon & Co. Common Stock is 10.35
When was Organon & Co. Common Stock last traded?
The last trade of Organon & Co. Common Stock was at 09/29/25 07:00 PM ET
What is the market capitalization of Organon & Co. Common Stock?
The market capitalization of Organon & Co. Common Stock is 2.62B
How many shares of Organon & Co. Common Stock are outstanding?
Organon & Co. Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.